NEW YORK (GenomeWeb News) – BioMarker Strategies today announced it is being granted a $1.5 million Small Business Innovation Research Phase II award to further develop its companion diagnostic for melanoma.

The grant from the National Cancer Institute will go toward the Baltimore, Md.-based firm's refinement of its PathMap assay and ex vivo protocols developed under a Phase I SBIR contract. The new funding will also support validation of PathMap in human clinical samples, BioMarker Strategies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.